Mylan Laboratories Limited – FDA 483, Feb 28, 2020
Mylan Laboratories Limited, Speciality Formulation Facility in Bangalore, India, was cited for significant deficiencies during an FDA inspection of its sterile drug manufacturing. The observations highlight inadequate laboratory controls, including unvalidated test methods and insufficient system suitability, as well as failures in out-of-specification investigations and quality control unit responsibilities. Additionally, issues were noted with process control procedures related to critical hold times and the scientific basis for environmental monitoring in aseptic areas.
ID · cca43c7c-0783-44c6-940e-2b1010e0ac93
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.